Introduction
============

Schizophrenia is a chronic psychiatric disease that has frequent relapses during the clinical course.[@b1-ndt-12-3243] A Cochrane database systematic review reported that 27% of schizophrenia patients experienced relapse within 12 months, even though they continued antipsychotic medication.[@b2-ndt-12-3243] Previous studies have also pointed out several risk factors for relapse, such as nonadherence to antipsychotics,[@b3-ndt-12-3243] interruption of treatment,[@b1-ndt-12-3243],[@b4-ndt-12-3243] lower quality of life (QOL),[@b5-ndt-12-3243] decreased cognitive function,[@b6-ndt-12-3243] poor premorbid adaptation to school,[@b2-ndt-12-3243] premorbid social withdrawal,[@b2-ndt-12-3243] shorter duration after the onset of schizophrenia,[@b7-ndt-12-3243] and involuntary hospitalization.[@b8-ndt-12-3243] A study with a long-term follow-up for ≥20 years revealed that the younger onset age of schizophrenia was significantly associated with the risk of relapse, while sex and marital status were not associated with relapse.[@b9-ndt-12-3243] Moreover, substance abuse, including benzodiazepines (BZPs) that were used as adjunctive medication for patients with schizophrenia, has been reported to increase the risk of relapse.[@b7-ndt-12-3243]

BZPs are widely used in clinical settings as adjunctive treatment for psychiatric diseases including schizophrenia. However, adverse effects of BZPs, especially with high-dose use, have been pointed out by several studies, such as risk of falling, fractures,[@b10-ndt-12-3243] nocturnal abnormal behavior,[@b11-ndt-12-3243] and risk of dependence.[@b12-ndt-12-3243],[@b13-ndt-12-3243] Since there has been no evidence about efficacy of BZPs in patients with schizophrenia as adjunctive treatment together with antipsychotics, this kind of drug is recommended only for short-term use for insomnia and anxiety.[@b14-ndt-12-3243] Nevertheless, 71%--86% of the patients with schizophrenia receive adjunctive treatment with BZPs in Japan; this rate seems to be higher than that in the United States.[@b15-ndt-12-3243] A recent research article reported that cognitive function and QOL were improved after reducing the amount of BZPs in patients with schizophrenia.[@b15-ndt-12-3243] Taking these studies into consideration, long-term and high-dose use of BZPs might affect the clinical course of schizophrenia. However, apparently no study focused on this issue.

Therefore, a naturalistic observational study focused on the relationship between high-dose BZPs and the clinical course of patients with schizophrenia for 2 years after hospital discharge was conducted. In addition, rehospitalization was targeted as a primary outcome in this study, which was a clear and clinically important indication of relapse in patients with schizophrenia.

Materials and methods
=====================

Subjects
--------

The subjects were selected from the Tokyo Medical University Hospital from January 2009 to February 2012. The subjects were diagnosed as having schizophrenia based on the diagnostic criteria of the *Diagnostic and Statistical Manual of Mental Disorders* (*DSM-IV-TR*) by at least two specialists in psychiatry. Patients who continued to have treatment in the outpatient clinic for ≥2 years were included. The cutoff period of this study was chosen as 2 years according to a previous study.[@b16-ndt-12-3243] Patients were excluded if they met the following criteria: 1) patients diagnosed with schizoaffective disorder or persistent delusional disorder; 2) patients who had physical diseases that might have an impact on the course of schizophrenia, including collagen disease, brain injury/stroke, dementia, and diabetes; and 3) those with a history of drug or alcohol abuse within the past 12 weeks. This study was conducted with the approval of the ethics committee of Tokyo Medical University which waived the requirement to obtain patient's consent due to the retrospective nature of the study.

Procedures
----------

Demographic and clinical parameters of the subjects, including age at the time of investigation, age at the onset of schizophrenia, sex, family members, marital status, educational history, working years, duration of illness of schizophrenia, length of stay at the last hospitalization, Global Assessment of Functioning (GAF) at the time of discharge, types of antipsychotics at the time of discharge, total doses of antipsychotics at the chlorpromazine (CP)-equivalent dose at the time of discharge, and total doses of BZP at the diazepam (DZP)-equivalent dose at the time of discharge were evaluated.

Statistical analysis
--------------------

At first, the subjects were divided into two groups: the rehospitalized group, who were rehospitalized within 2 years after discharge from the previous hospitalization, and the non-rehospitalized group. Student's *t*-test and the chi-squared test were used to compare the demographic and clinical parameters between the two groups. The Kaplan--Meier method was used to calculate the cumulative survival rates of the subjects. Analysis with the Cox proportional hazards model was performed for the factors associated with time to rehospitalization. All variables were analyzed as categorical variables. Continuous variables, including age at the time of investigation, age at the onset of schizophrenia, working years, duration of schizophrenia morbidity, duration of hospitalization, GAF, CP-equivalent dose of antipsychotics, and DZP-equivalent dose of BZPs, were divided by the median values and analyzed as categorical variables. In the Cox proportional hazard analysis, variables that showed significant association in univariate analyses were put into a multivariate model. SPSS Version 19 (SPSS Inc., Chicago, IL, USA) was used for all the statistical analyses. The significance level was set at *P*\<0.05.

Results
=======

One hundred and ninety-three patients aged 18--65 years who were discharged from the hospital met the inclusion criteria for schizophrenia. Finally, 108 patients (55%) who continued to have treatment in the outpatient clinic for ≥2 years were included in this study. In 108 subjects with schizophrenia, 44 subjects (40.7%) experienced rehospitalization during the 2-year study period. The Kaplan--Meier method revealed cumulative survival rates ([Figure 1](#f1-ndt-12-3243){ref-type="fig"}).

Comparison of demographic and clinical parameters between the rehospitalized group and non-rehospitalized group is shown in [Table 1](#t1-ndt-12-3243){ref-type="table"}. Age at the time of discharge and age at the onset of schizophrenia in the rehospitalized group were significantly lower than those in the non-rehospitalized group. The rate of the number of patients with college graduation in the rehospitalized group was significantly lower than that in the non-rehospitalized group. Lifetime working years in the rehospitalized group was significantly shorter than that in the non-rehospitalized group. The CP-equivalent dose and DZP-equivalent dose in the rehospitalized group were significantly higher than those in the non-rehospitalized group.

Univariate analyses of the Cox proportional hazard model revealed that age at the time of discharge, age at the onset of schizophrenia, college graduation, lifetime working years, CP-equivalent dose, and DZP-equivalent dose were significantly associated with rehospitalization after discharge. Multivariate analysis by the Cox proportional hazards model with step-wise method revealed that low educational history, younger age of onset of schizophrenia, and higher DZP-equivalent dose were significantly associated with time to rehospitalization after discharge ([Table 2](#t2-ndt-12-3243){ref-type="table"} and [Figure 1](#f1-ndt-12-3243){ref-type="fig"}).

Discussion
==========

This may be the first study to reveal the relationship between the high-dose usage of BZPs and the clinical course of patients with schizophrenia. The result of this study showed that high-dose use of BZPs (\>10 mg DZP-equivalent dose), lower educational history, and younger onset age of schizophrenia were significantly associated with time to rehospitalization. On the other hand, lower-dose use of BZPs (\<10 mg) was not associated with the duration of rehospitalization. Our previous studies suggested that BZPs lead to abnormal behavior during sleep[@b11-ndt-12-3243] and risk of dependency on BZPs[@b12-ndt-12-3243] in schizophrenic patients. In addition to these adverse effects of BZPs on schizophrenia, the results of this study suggest that BZPs might worsen the clinical course of schizophrenia (relapse in particular) as the dose increases.

The causal relationship between high-dose usage of BZPs and rehospitalization in patients with schizophrenia was unclear in this study. However, a previous study suggested a negative effect of high-dose use of BZPs on patients with schizophrenia. Kitajima et al[@b15-ndt-12-3243] investigated the effect of reducing BZP doses on cognitive function of schizophrenic patients for 8 weeks and revealed that cognitive function was improved significantly in them after reducing BZP doses, compared with the control patients. It is possible that high-dose use of BZPs reduces cognitive function, consequently leading to worsening symptoms of schizophrenia. In addition, a large case--control study suggested that concomitant usage of BZP was related to the risk of death in schizophrenic patients.[@b17-ndt-12-3243] Similarly, it was reported that concomitant use of BZP with intramuscular depot formulations of olanzapine possibly increased the death rate in schizophrenia patients.[@b18-ndt-12-3243] Therefore, psychiatrists should pay attention to concomitant use of BZP for schizophrenia patients. Finally, there is a possibility that BZP usage may lower the adherence to antipsychotic medication, although apparently no study has investigated this issue.

On the other hand, it is also possible that schizophrenic patients with severe symptoms, including insomnia and anxiety, which are target symptoms of BZPs, are likely to have high doses of BZPs.[@b19-ndt-12-3243] However, considering the result of our study that GAF scores at hospital discharge were not significantly associated with rehospitalization, high-dose use of BZPs might affect the clinical course of schizophrenia. Although the results of this study could not clarify how high-dose usage of BZPs affects the clinical course of schizophrenia, clinicians should avoid using high-dose BZPs because previous studies have suggested that BZPs did not improve any clinical outcome of schizophrenia.[@b14-ndt-12-3243]

The results of this study pointed out that younger onset age of schizophrenia and lower educational history were also factors associated with time to rehospitalization, which were similar to the results of previous studies. Eaton et al[@b9-ndt-12-3243] suggested that lower onset age of schizophrenia was associated with rehospitalization after the initial hospital discharge, as a result of multivariate Cox proportional analysis for \>20 years follow-up.[@b9-ndt-12-3243] In addition, Suzuki et al[@b20-ndt-12-3243] performed a multiple logistic regression analysis for factors associated with rehospitalization in 67 outpatients with schizophrenia and revealed that lower educational history was significantly associated with rehospitalization. The results of these two studies were in line with the results of the present study and might support the validity of the results.

This study has several limitations. First, because the sample size of this study was relatively small due to this being a single-center study, the subjects of this study were not a representative population of schizophrenia patients in Japan. Second, treatment in this study was not controlled; there may be some treatment biases in this study. Third, because this study focused on doses of antipsychotics and BZPs, any other drugs, including anticholinergic drugs, which were reported to affect cognitive function in patients with schizophrenia were not evaluated.[@b21-ndt-12-3243] Fourth, several clinical characteristics of the subjects, some of which were also reported to be associated with relapse, were also not evaluated.[@b2-ndt-12-3243] Fifth, because subjects who were discharged between 2009 and 2012 were studied, the result of this study might not reflect the current clinical care situation. Sixth, because this study was not conducted by an intention-to-treat analysis and the entire discharged schizophrenia cohort was not included, the effect of BZP usage on rehospitalization might be biased by these methodological issues. Seventh, because this study was conducted using a retrospective design, a prospective and longitudinal study will be needed to confirm the relationship between continuing usage of benzodiazepine and rehospitalization.

Conclusion
==========

In conclusion, high-dose use of BZPs, as well as younger onset age and lower educational history, in patients with schizophrenia might be associated with a shorter time to rehospitalization. In the future, a controlled study with a larger population will be required to confirm our findings. Clinicians should take care while prescribing higher doses of BZPs in order to avoid adverse events in the treatment of schizophrenia.

We are indebted to the medical editors of the Department of International Medical Communications at Tokyo Medical University for editing and reviewing the initial English manuscript.
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###### 

Comparison of demographic and clinical parameters of the subjects between the rehospitalized group and non-rehospitalized group

  --------------------------------------------------------------------------------------------------------------------
  Variables                                          Overall\      Rehospitalized\   Non-rehospitalized\   *P*-value
                                                     (n=108)       (n=44)            (n=64)                
  -------------------------------------------------- ------------- ----------------- --------------------- -----------
  Age at the time of discharge, years                44.1±16.3     38.1±13.9         48.1±16.7             0.001

  Onset age of schizophrenia, years                  29.9±14.0     25.2±11.0         33.0±14.9             0.003

  Sex (male:female)                                  30:78         9:35              21:43                 0.193

  Living with family (yes:no)                        80:28         37:7              4:21                  0.073

  Marital status (married:unmarried)                 25:83         9:35              16:48                 0.648

  College graduation (yes:no)                        32:76         7:37              25:39                 0.011

  Life-time working years                            8.8±11.9      5.5±7.8           11.1±13.7             0.010

  Duration of schizophrenia, years                   15.0±13.2     14.1±12.5         15.6±13.8             0.539

  Length of stay, days                               44.7±51.4     48.3±68.0         42.3±36.3             0.593

  GAF scores at the time of discharge, points        56.6±12.8     55.4±9.8          57.3±14.4             0.400

  CP-equivalent dose at the time of discharge, mg    506.1±364.3   609.7±416.3       434.9±307.5           0.020

  DZP-equivalent dose at the time of discharge, mg   12.3±11.2     18.5±12.4         8.0±7.8               \<0.001
  --------------------------------------------------------------------------------------------------------------------

**Notes:** The values represent the mean ± SD. Student's *t*-test was used to compare the continuous variables between the two groups. The chi-squared test was used to compare the categorical variables.

**Abbreviations:** GAF, Global Assessment of Functioning; CP, chlorpromazine; DZP, diazepam.

###### 

Multivariate Cox hazard proportional analysis for factors associated with time to rehospitalization

  Variables                 Hazard ratio (95% CI)   *P*-value
  ------------------------- ----------------------- -----------
  College graduation                                
   Yes                      (ref)                   
   No                       2.43 (1.08--5.48)       0.032
  Age at the onset, years                           
   ≧25                      (ref)                   
   \<25                     2.10 (1.12--3.94)       0.021
  DZP-equivalent dose, mg                           
   0                        (ref)                   
   \<10                     2.73 (0.62--11.10)      NS
   ≧10                      6.54 (1.54--27.73)      0.011

**Abbreviations:** NS, not significant; DZP, diazepam; ref, reference; CI, confidence interval.
